Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
specificThe reemergence of diffuse large B-cell lymphoma, not otherwise specified after a period of remission.
16
Centers
16
Active Trials
—
Cancer Funding
Top Centers for Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified(16)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive High-Volume Research Center | 74.2 |
| 2 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 53.1 |
| 3 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive Active Research Program | 53.1 |
| 4 | NCI Comprehensive Active Research Program | 53.1 |
| 5 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 53.1 |
| 6 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 53.1 |
| 7 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 53.1 |
| 8 | Cedars-Sinai CancerLos Angeles, CA Active Research Program | 53.1 |
| 9 | VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive Active Research Program | 53.1 |
| 10 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 53.1 |
| 11 | University of Illinois Cancer CenterChicago, IL Active Research Program | 53.1 |
| 12 | Cancer Center at IllinoisUrbana, IL Active Research Program | 53.1 |
| 13 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 53.1 |
| 14 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL Active Research Program | 53.1 |
| 15 | The University of Vermont Cancer CenterBurlington, VT Active Research Program | 53.1 |
| 16 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive | 32.0 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →